Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung

This publication has 31 references indexed in Scilit:

• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
  The Lancet, 2010
• Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer
  Clinical Cancer Research, 2010
• Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
  Journal of Clinical Oncology, 2009
• Assessment of a HER2 scoring system for gastric cancer: results from a validation study
  Histopathology, 2008
• Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study)
  Annals of Oncology, 2007
• ERBB receptors and cancer: the complexity of targeted inhibitors
  Nature Reviews Cancer, 2005
• Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb‐B2
  Cancer, 2005
• Lack of prognostic implications of HER‐2/neu abnormalities in 345 stage I nonsmall cell carcinomas (NSCLC) and 207 stage I–III neuroendocrine tumours (NET) of the lung
  International Journal of Cancer, 2004
• Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
  Journal of Clinical Oncology, 2002
• Tissue microarrays for high-throughput molecular profiling of tumor specimens
  Nature Medicine, 1998